Eli Lilly provides in-line 2014 guidance

Eli Lilly (LLY) expects 2014 EPS of $2.77-$2.85 vs consensus of $2.78, with the company's guidance "reflecting the impact of patent expirations."

Forecasts revenue of $19.2-19.8B vs Street estimates of $19.55B.

Sees net income at $3B and operating cash flow of $4B.

Reaffirms commitment to maintain dividend at least at current level.

Late-stage pipeline includes 13 medicines in Phase III development or submission stage.

Eli Lilly's 2013 financial expectations remain unchanged. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs